Hologic Inc Revenue Growth Rates (HOLX), Current and Historic Growth - CSIMarket
CSIMarket
 


Hologic Inc  (NASDAQ: HOLX)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

HOLX's Revenue Growth by Quarter and Year

Hologic Inc's Revenue results by quarter and year




HOLX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June -
2nd Quarter March -
1st Quarter December 907.40
FY 907.40

HOLXs Annual Revenue
Hologic Inc's Revenue in the fiscal year 2025 $ 3,363.90 millions
Hologic Inc's Revenue in the fiscal year 2024 $ 2,407.80 millions
Hologic Inc's Revenue in the fiscal year 2023 $ 2,276.50 millions
Hologic Inc's Revenue in the fiscal year 2022 $ 3,293.10 millions
Hologic Inc's Revenue in the fiscal year 2021 $ 5,277.60 millions




HOLX Revenue first quarter 2026 Y/Y Growth Comment
Hologic Inc achieved in the first quarter 2026, above Company average Revenue rise of 44.84% year on year, to $ 907.40 millions.

Among companies who have reported first quarter 2026 results in the Medical Laboratories industry only one Company has achieved higher year on year Revenue results in the first quarter 2026. While Hologic Inc' s Revenue jump of 44.84% ranks overall at the positon no. 235 in the first quarter 2026.




HOLX Revenue ( Y/Y Growth %) 2026
2025 2024 2023
4th Quarter September - 71.51 % 4.52 % -0.81 %
3rd Quarter June - 2.2 % -38.61 % -1.83 %
2nd Quarter March - -58.21 % -0.85 % -28.5 %
1st Quarter December 44.84 % -38.16 % -5.69 % -26.98 %
FY   - -7.16 % -10.1 % -

Financial Statements
Hologic Inc's first quarter 2026 Revenue $ 907.40 millions HOLX's Income Statement
Hologic Inc's first quarter 2025 Revenue $ 626.50 millions Quarterly HOLX's Income Statement


HOLX Revenue (Quarter on Quarter Growth %)

2026
2025 2024 2023
4th Quarter September - 174.37 % 63.49 % -3.97 %
3rd Quarter June - 45.22 % -40.63 % -4.1 %
2nd Quarter March - -32.11 % 0.46 % -4.44 %
1st Quarter December -46.45 % -36.59 % 7.17 % 12.72 %
FY (Year on Year)   - -7.16 % -10.1 % -




Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #19
Overall #235

Revenue Y/Y Growth Statistics
High Average Low
153.41 % -1469.02 % -63483.34 %
(Jun 26 2021)   (Sep 30 2023)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #19
Overall #235
Revenue Y/Y Growth Statistics
High Average Low
153.41 % -1469.02 % -63483.34 %
(Jun 26 2021)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Hologic Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
174.37 % 2.44 % -100 %
(Sep 27 2025)  


HOLX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Hologic Inc disclosed fall in Revenue from the fourth quarter by -46.45% to $ 907.40 millions, from $ 1,694.50 millions achived in the previous reporting period.

But that's not important problem, as Hologic Inc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry Hologic Inc achieved highest sequential Revenue growth. While Hologic Inc's Revenue growth quarter on quarter, overall rank is 261.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #19
Overall #261
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #19
Overall #261
Revenue Q/Q Growth Statistics
High Average Low
174.37 % 2.44 % -100 %
(Sep 27 2025)  


HOLX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Hologic Inc disclosed fall in Revenue from the fourth quarter by -46.45% to $ 907.40 millions, from $ 1,694.50 millions achived in the previous reporting period.

But that's not important problem, as Hologic Inc's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry Hologic Inc achieved highest sequential Revenue growth. While Hologic Inc's Revenue growth quarter on quarter, overall rank is 261.


Hologic Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 27 2025)
12 Months Ending
(Sep 27 2025)
12 Months Ending
(Jun 28 2025)
12 Months Ending
(Mar 29 2025)
12 Months Ending
(Dec 28 2024)
Cumulative Revenue 12 Months Ending $ 3,644.80 $ 3,363.90 $ 2,657.40 $ 2,644.10 $ 3,236.60
Y / Y Revenue Growth (TTM) 12.61 % -7.16 % -25.78 % -33.24 % -18.46 %
Year on Year Revenue Growth Overall Ranking # 244 # 2174 # 1915 # 690 # 651
Seqeuential Revenue Change (TTM) 8.35 % 26.59 % 0.5 % -18.31 % -10.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 1232 # 2177 # 1920 # 686 # 523


Cumulative Revenue growth Comment
Hologic Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,645 millions if the fiscal year would have ended in Dec 27 2025.
Hologic Inc's trailing twelve months Revenue growth was higher than company's average -1469.02% and higher than -7.16% growth in Sep 27 2025.
But from twelve months ended Sep 27 2025 rise was beneth at 8.35 % from $3363.9 millions achieved in the period from Sep 27 2025 to Dec 28 2024.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -1469.02%.
The momentum is even more impressive from twelve months ended Sep 27 2025 exhibited at 8.35 % increase from $3363.9 millions in the period from Sep 27 2025 to Dec 28 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 244, from total ranking in previous quarter at 2174.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 10
Healthcare Sector # 20
Overall # 244

Revenue TTM Y/Y Growth Statistics
High Average Low
153.41 %
-1469.02 %
-63483.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 133
S&P 500 # 1232
Cumulative Revenue growth Comment
Hologic Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 12.61% year on year, to $ 3,645 millions if the fiscal year would have ended in Dec 27 2025.
Hologic Inc's trailing twelve months Revenue growth was higher than company's average -1469.02% and higher than -7.16% growth in Sep 27 2025.
But from twelve months ended Sep 27 2025 rise was beneth at 8.35 % from $3363.9 millions achieved in the period from Sep 27 2025 to Dec 28 2024.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at -1469.02%.
The momentum is even more impressive from twelve months ended Sep 27 2025 exhibited at 8.35 % increase from $3363.9 millions in the period from Sep 27 2025 to Dec 28 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 244, from total ranking in previous quarter at 2174.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 10
Healthcare Sector # 20
Overall # 244

Revenue TTM Y/Y Growth Statistics
High Average Low
153.41 %
-1469.02 %
-63483.34 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 133
S&P 500 # 1232




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HOLX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Dec 27 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 27 2025
Organogenesis Holdings Inc 78.13%$ 78.126 millions
Tg Therapeutics Inc 78.00%$ 78.004 millions
Eton Pharmaceuticals Inc 77.14%$ 77.140 millions
Trisalus Life Sciences Inc 76.95%$ 76.954 millions
Co diagnostics Inc 76.74%$ 76.743 millions
Ss Innovations International Inc76.54%$ 76.537 millions
Cellectis S a 75.76%$ 75.760 millions
Fennec Pharmaceuticals Inc 73.84%$ 73.842 millions
Travere Therapeutics Inc 73.41%$ 73.410 millions
Inspiremd Inc 69.30%$ 69.299 millions
Viridian Therapeutics Inc 68.06%$ 68.056 millions
Sol gel Technologies Ltd 68.04%$ 68.036 millions
Novavax inc 66.61%$ 66.615 millions
Beyond Air Inc 65.61%$ 65.605 millions
Axsome Therapeutics Inc 65.03%$ 65.030 millions
Kiniksa Pharmaceuticals International Plc64.95%$ 64.953 millions
Precision Optics Corporation Inc 62.76%$ 62.757 millions
Organigram Global Inc 62.15%$ 62.151 millions
Cardiff Oncology Inc 62.00%$ 62.000 millions
Beta Bionics Inc 61.17%$ 61.174 millions
Catheter Precision Inc 59.73%$ 59.732 millions
Euda Health Holdings Limited59.29%$ 59.292 millions
Xoma Royalty Corporation57.87%$ 57.872 millions
Immuron Limited55.99%$ 55.993 millions
Ideaya Biosciences Inc 55.37%$ 55.371 millions
Urogen Pharma Ltd 54.03%$ 54.028 millions
The Pennant Group Inc 53.17%$ 53.168 millions
Halozyme Therapeutics Inc 51.60%$ 51.596 millions
Nephros Inc 51.08%$ 51.084 millions
Adaptive Biotechnologies Corporation51.04%$ 51.038 millions


About Hologic Inc Revenue Growth Rates (HOLX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Hologic Inc (CIK 859737).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000859737-26-000008
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Hologic Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.